CD19 and acute lymphoblastic leukemia: In fact, CD19 CAR T-cell therapy for acute lymphoblastic leukemia (ALL) in children and adults with relapsed and refractory disease have achieved remarkable efficacy with up to 90% complete response rate4,7,8.